Weekly Paclitaxel, Carboplatin, and Cetuximab as First-Line Treatment of Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma for Patients Ineligible to Cisplatin-Based Chemotherapy: A Retrospective Monocentric Study in 60 Patients.
Fiche publication
Date publication
janvier 2021
Journal
Frontiers in oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Dr BOREL Christian, Dr GUIHARD Sébastien, Dr JUNG Alain, Pr PETIT Thierry, Dr DEMARCHI Martin, Dr COLIAT Pierre, Dr BURGY Mickaël
Tous les auteurs :
Carinato H, Burgy M, Ferry R, Fischbach C, Kalish M, Guihard S, Brahimi Y, Flesch H, Bronner G, Schultz P, Frasie V, Thiéry A, Demarchi M, Petit T, Jung AC, Wagner P, Coliat P, Borel C
Lien Pubmed
Résumé
For most patients suffering from recurrent and/or metastatic head and neck squamous cell carcinoma (R/M HNSCC), chemotherapy is the main option after considering surgery and reirradiation. Cetuximab combined with a platinum-fluorouracil regimen (EXTREME) has been the standard of care for over a decade. Nevertheless, a significant number of patients remain unfit for this regimen because of age, severe comorbidities, or poor performance status. The aim of this study is to investigate an alternative regimen with sufficient efficacy and safety.
Mots clés
carboplatin, cetuximab, chemotherapy, first-line, head and neck squamous cell carcinoma, paclitaxel, recurrent or metastatic
Référence
Front Oncol. 2021 ;11:714551